Rhumbline Advisers Vor Biopharma Inc. Transaction History

Rhumbline Advisers

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.0 - $2.2 $38,165 - $83,963	-38,165 Reduced 87.39%	5,505 $5,000
Q1 2024 May 09, 2024	BUY	$1.8 - $2.85 $1,224 - $1,938	680 Added 1.58%	43,670 $103,000
Q4 2023 Feb 08, 2024	SELL	$1.66 - $2.63 $3,173 - $5,028	-1,912 Reduced 4.26%	42,990 $96,000
Q3 2023 Nov 09, 2023	BUY	$2.1 - $3.35 $4,813 - $7,678	2,292 Added 5.38%	44,902 $95,000
Q2 2023 Aug 08, 2023	BUY	$3.09 - $5.33 $131,664 - $227,111	42,610 New	42,610 $131,000
Q2 2022 Aug 11, 2022	SELL	$3.89 - $6.44 $63,531 - $105,178	-16,332 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$6.04 - $12.23 $12,080 - $24,460	-2,000 Reduced 10.91%	16,332 $99,000
Q4 2021 Feb 10, 2022	BUY	$11.32 - $18.02 $33,122 - $52,726	2,926 Added 18.99%	18,332 $213,000
Q3 2021 Nov 12, 2021	BUY	$12.24 - $20.38 $47,356 - $78,850	3,869 Added 33.54%	15,406 $242,000
Q2 2021 Aug 05, 2021	BUY	$18.65 - $38.78 $35,975 - $74,806	1,929 Added 20.08%	11,537 $215,000
Q1 2021 May 06, 2021	BUY	$30.96 - $54.08 $297,463 - $519,600	9,608 New	9,608 $414,000

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $32.7M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.